Clinical trial
Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases
NCT00393965 · Myrexis Inc., Industry · Completed
Key facts
| NCT number | NCT00393965 |
|---|---|
| Title | Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases |
| Official title | Phase 1 Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Brain Metastases |
| Lead sponsor | Myrexis Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain Neoplasms |
| Intervention type | Drug |
| Interventions | MPC-6827 |
| Enrollment | 18 |
| Start date | Dec 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | Oct 31, 2006 |
| Last update posted | Feb 13, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: